VivoSeq
Other

Asthenia

11

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Asthenia is an emerging landscape with 11 programs across 3 companies. The most active players are UCB, Novartis, Novo Nordisk. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

78/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

UCB logo

UCB

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3Novo Nordisk logo

Novo Nordisk

2 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

13 of 14 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody17%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

16

clinical trials

Completed7 · 44%
Unknown status3 · 19%
No longer available2 · 13%
Terminated2 · 13%
Recruiting1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
Recruiting·FFondation Ophtalmologique Adolphe de Rothschild·Phase 3·NCT06342544·128 enrolled
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
Active, not recruiting·—·Phase 1/2·NCT06211634·57 enrolled
Observational Registry of the Treatment of Glanzmann's Thrombasthenia
Completed·Novo Nordisk logoNovo Nordisk·N/A·NCT01476423·218 enrolled
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
Completed·Novo Nordisk logoNovo Nordisk·N/A·NCT01876745·4 enrolled
Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19
Completed·PPromomed, LLC·Phase 4·NCT05939622·30 enrolled
A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders
Completed·VValenta Pharm JSC·Phase 3·NCT05586789·220 enrolled
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)
Completed·UUniversity Hospital, Bordeaux·N/A·NCT04595617·28 enrolled
Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19
Completed·PPromomed, LLC·Phase 4·NCT05689827·160 enrolled
Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.
Completed·MMateria Medica Holding·Phase 3·NCT05074888·676 enrolled
Efficacy of Prednisone In the Treatment of Ocular Myasthenia
Terminated·—·Phase 3·NCT00995722·11 enrolled
Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients
Terminated·—·Phase 3·NCT01773837·100 enrolled
A Clinical Study of Gulingji Capsule in the Treatment of Idiopathic Oligospermia, Asthenia, and Teratozoospermia
Unknown status·JJinling Hospital, China·Phase 4·NCT05320536·240 enrolled
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
No longer available·OOregon Health and Science University·N/A·NCT02012933
Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia
Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02363075·58 enrolled
Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
No longer available·—·N/A·NCT03062631
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)